All In Biotech

Drug Trial Radar · NCT03138629

Expanded Access to VAL-083

Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Kintara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 3, 2017

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

  • Cancer

Interventions

  • VAL-083Drug

    VAL-083 will be administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.